Risk stratification schemes, anticoagulation use and outcomes: the risk--treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation

Sandhu, Roopinder K.; Bakal, Jeffrey A.; Ezekowitz, Justin A.; McAlister, Finlay A.
December 2011
Heart;Dec2011, Vol. 97 Issue 24, p2046
Academic Journal
Objective To examine whether warfarin use and outcomes differ across CHADS2 and CHA2DS2-VASc risk strata for non-valvular atrial fibrillation (NVAF). Design Population-based cohort study using linked administrative databases in Alberta, Canada. Setting Inpatient and outpatient. Patients 42 834 consecutive patients ≥20 years of age with newly diagnosed NVAF. Main outcome measures Cerebrovascular events and/ or mortality in the first year after diagnosis. Results Of 42 834 NVAF patients, 22.7% were low risk on the CHADS2 risk score (0), 27.5% were intermediate risk (1), and 49.8% were high risk (≥2). The CHA2DS2-VASc risk score reclassified 16 722 patients such that 7.8% were defined low risk, 13.8% intermediate risk and 78.4% high risk. Of the elderly cohort (≥65 years) with definite NVAF visits (at least two encounters 30 days apart, n=8780), 49% were taking warfarin within 90 days of diagnosis. Warfarin use did not differ across risk strata using either the CHADS2 (p for trend=0.85) or CHA2DS2-VASC (p=0.35). In multivariable adjusted analyses, warfarin use was associated with substantially lower rates of death or cerebrovascular events for patients with CHADS2 scores of 1 (OR 0.52, 95% CI 0.41 to 0.67) or ≥2 (OR 0.61, 95% CI 0.53 to 0.71), or CHA2DS2-VASc scores of ≥2 (OR 0.60, 95% CI 0.53 to 0.68). Conclusions In elderly patients with NVAF and elevated CHADS2 or CHA2DS2-VASC scores, warfarin users exhibited lower rates of cerebrovascular events and mortality. However, warfarin use did not differ across risk strata, another example of the risk--treatment paradox in cardiovascular disease.


Related Articles

  • Dabigatran vs warfarin: Less bleeding?  // Internal Medicine Alert;11/17/2009 Supplement, p21 

    The article reports on the results of a study regarding the effective use of dabigatran (DAB) and warfarin (WRF) in the reduction of atrial fibrilation (AF) risk factors.

  • The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Buiten, M. S.; de Bie, M. K.; Rotmans, J. I.; Gabreëls, B. A.; van Dorp, W.; Wolterbeek, R.; Trines, S. A.; Schalij, M. J.; Jukema, J. W.; Rabelink, T. J.; van Erven, L. // Heart;May2014, Vol. 100 Issue 9, p685 

    Aims Atrial fibrillation (AF) is common in dialysis patients and is associated with increased morbidity and mortality. The pathophysiology may be related to common risk factors for both AF and renal disease or to dialysis-specific factors. The purpose of this study was to determine whether and...

  • Stroke risk estimation across nine European countries in the MORGAM project. Borglykke, Anders; Andreasen, Anne H.; Kuulasmaa, Kari; Sans, Susana; Ducimetière, Pierre; Vanuzzo, Diego; Ferrario, Marco M.; Palmieri, Luigi; Karvanen, Juha; Tunstall-Pedoe, Hugh; Jørgensen, Torben // Heart;Dec2010, Vol. 96 Issue 24, p1997 

    Background Previous tools for stroke risk assessment have either been developed for specific populations or lack data on non-fatal events or uniform data collection. The purpose of this study was to develop a stepwise model for the estimation of 10⇔…year risk of stroke in nine...

  • Preventing stroke: Who should take warfarin? Sgammato, Joseph // Patient Care;12/15/1994, Vol. 28 Issue 20, p27 

    Examines a study on the use of long-term warfarin therapy in reducing the risk of stroke. Patients with nonvalvular atrial fibrillation as subjects of the study; Clinical trials; Relative risk factors.

  • Subclinical atrial fibrillation: how hard should we look? Wachter, Rolf; Stahrenberg, Raoul; Gröschel, Klaus // Heart;Feb2013, Vol. 99 Issue 3, p151 

    The authors discuss the risk factors associated with atrial fibrillation (AF). According to Framingham Heart Study, atrial fibrillation enhances the probability of stroke by a factor of five in non-rheumatic AF and by a factor of 17 in rheumatic AF. They also discuss the data released by the...

  • Effect of Race/Ethnicity on the Efficacy of Warfarin: Potential Implications for Prevention of Stroke in Patients with Atrial Fibrillation. Shen, Albert Yuh-Jer; Chen, Wansu; Yao, Janis F; Brar, Somjot S; Wang, Xunzhang; Go, Alan S // CNS Drugs;2008, Vol. 22 Issue 10, p815 

    Atrial fibrillation (AF) is the most common sustained arrhythmia seen in clinical practice. It affects approximately 6% of persons over 65 years of age and is independently associated with a 4- to 5-fold higher risk of ischaemic stroke and a 2-fold higher risk of death. Randomized controlled...

  • New Blood Thinners Make Life Easier for Many.  // Heart Advisor;Jan2015, Vol. 18 Issue 1, p6 

    The article discusses the benefits of blood thinners like warfarin or a novel oral anti-coagulant (NOAC) to patients at risk with atrial fibrillation. It explores the advantages of NOACs over warfarin, including their effectiveness, possible risks, and complications. Cleveland Clinic...

  • Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients With Atrial Fibrillation. Bruins Slot, Karsten M. H.; Berge, Eivind // JAMA: Journal of the American Medical Association;3/19/2014, Vol. 311 Issue 11, p1150 

    The article discusses the use of factor XA inhibitors as an alternative for preventing strokes or other systemic embolic events in patients with atrial fibrillation. Topics discussed include the primary outcome of nine trials focused on treatment with a factor Xa inhibitor that revealed an...

  • Treating Atrial Fibrillation. Wang, Debbie; Conover, Damien // Morningstar StockInvestor;11/15/2009, Vol. 9 Issue 5, p26 

    The article presents the author's views on the aspects and risks of atrial fibrillation that can potentially cause blood clot and lead to stroke. The author muses on the decisions of physicians to medicate patients on anticoagulation therapy with the drug Warfarin which brings bleeding risks....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics